Autologous stromal vascular fraction therapy for rheumatoid arthritis: Rationale and clinical safety

Jorge Paz Rodriguez, Michael P. Murphy, Soonjun Hong, Marialaura Madrigal, Keith L. March, Boris Minev, Robert J. Harman, Chien Shing Chen, Ruben Berrocal Timmons, Annette M. Marleau, Neil H. Riordan

Research output: Contribution to journalArticle

Abstract

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

Original languageEnglish
Pages (from-to)5
Number of pages1
JournalInternational Archives of Medicine
DOIs
StateAccepted/In press - Feb 8 2012
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Autologous stromal vascular fraction therapy for rheumatoid arthritis: Rationale and clinical safety'. Together they form a unique fingerprint.

  • Cite this

    Paz Rodriguez, J., Murphy, M. P., Hong, S., Madrigal, M., March, K. L., Minev, B., Harman, R. J., Chen, C. S., Timmons, R. B., Marleau, A. M., & Riordan, N. H. (Accepted/In press). Autologous stromal vascular fraction therapy for rheumatoid arthritis: Rationale and clinical safety. International Archives of Medicine, 5. https://doi.org/10.1186/1755-7682-5-5